Stock Scorer

Ligand Pharmaceuticals Inc (LGND)

Ligand Pharmaceuticals Inc reported revenue of 63.7M USD for the quarter ending 30 June 2026, up 33.7% from 47.6M a year earlier.

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than filled in. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD. The same series drawn ›

As last reported

The newest period the filing supports for each figure, in USD.
FigurePeriodAmountYear on year
Revenue Q2 '26 · ending 30 June 2026 63.7M +33.7%
Gross Profit Q3 '19 · ending 30 September 2019 21.7M -51.0%
Operating Income Q2 '26 · ending 30 June 2026 8.6M +1.7%
Net Income Q2 '26 · ending 30 June 2026 48.5M +900.8%
Cost of Revenue Q3 '19 · ending 30 September 2019 3.1M +115.5%
Operating Cash Flow Q2 '26 · ending 30 June 2026 24M +52.0%
Free Cash Flow Q2 '26 · ending 30 June 2026 24M +53.9%
Shares Outstanding Q2 '26 · ending 30 June 2026 21.8M +13.8%
EPS Q2 '26 · ending 30 June 2026 9.41 —

Revenue and profit by financial year

As filed, in USD. A year the filing does not support is not listed.
YearEnding RevenueOperating IncomeNet IncomeFree Cash Flow
20252025-12-31 268.1M41M124.5M48.9M
20242024-12-31 167.1M-22.6M-4M95.2M
20232023-12-31 131.3M11.9M52.2M46.1M
20222022-12-31 196.2M3M-33.4M119.9M
20212021-12-31 241.5M103.9M57.1M70M
20202020-12-31 163.6M37.5M-3M50.1M
20192019-12-31 120.3M807.1M629.3M-31.9M
20182018-12-31 251.5M163.7M143.3M193.2M
20172017-12-31 141.1M68.1M12.6M86.4M
20162016-12-31 109M43.9M-1.6M58.9M

Every period

Revenue Quarterly

PeriodEndingRevenue
Q2 '262026-06-3063.7M
Q1 '262026-03-3151.7M
Q4 '252025-12-3159.7M
Q3 '252025-09-30115.5M
Q2 '252025-06-3047.6M
Q1 '252025-03-3145.3M
Q4 '242024-12-3142.8M
Q3 '242024-09-3051.8M
Q2 '242024-06-3041.5M
Q1 '242024-03-3131M
Q4 '232023-12-3128.1M
Q3 '232023-09-3032.9M
Q2 '232023-06-3026.4M
Q1 '232023-03-3144M
Q4 '222022-12-3150.4M
Q3 '222022-09-3059.2M
Q2 '222022-06-3050.1M
Q1 '222022-03-3136.5M
Q4 '212021-12-3156.4M
Q3 '212021-09-3064.8M

Gross Profit Quarterly

Revenue minus cost of sales. This filer tags no gross profit of its own..

PeriodEndingGross Profit
Q3 '192019-09-3021.7M
Q2 '192019-06-3022.6M
Q1 '192019-03-3139.6M
Q4 '182018-12-3156.6M
Q3 '182018-09-3044.2M
Q2 '182018-06-3088.9M
Q1 '182018-03-3155.4M
Q4 '172017-12-3157.9M
Q3 '172017-09-3043.3M
Q2 '172017-06-3089.1M
Q1 '172017-03-3155.8M

Operating Income Quarterly

PeriodEndingOperating Income
Q2 '262026-06-308.6M
Q1 '262026-03-3117.4M
Q4 '252025-12-3113.8M
Q3 '252025-09-3054.9M
Q2 '252025-06-308.4M
Q1 '252025-03-31-36.2M
Q4 '242024-12-31-9.6M
Q3 '242024-09-303.1M
Q2 '242024-06-30-19.1M
Q1 '242024-03-313M
Q4 '232023-12-31-3.4M
Q3 '232023-09-303.1M
Q2 '232023-06-30-2M
Q1 '232023-03-3114.2M
Q3 '222022-09-3012.3M
Q2 '222022-06-308.7M
Q1 '222022-03-312.1M
Q4 '212021-12-3137.7M
Q3 '212021-09-3015.7M
Q2 '212021-06-3045.7M

Net Income Quarterly

PeriodEndingNet Income
Q2 '262026-06-3048.5M
Q1 '262026-03-31-13.3M
Q4 '252025-12-3144.8M
Q3 '252025-09-30117.3M
Q2 '252025-06-304.8M
Q1 '252025-03-31-42.5M
Q4 '242024-12-31-31.1M
Q3 '242024-09-30-7.2M
Q2 '242024-06-30-51.9M
Q1 '242024-03-3186.1M
Q4 '232023-12-3118.2M
Q3 '232023-09-30-10.3M
Q2 '232023-06-302.3M
Q1 '232023-03-3141.9M
Q4 '222022-12-31-17.5M
Q3 '222022-09-30404K
Q2 '222022-06-30-895K
Q1 '222022-03-31-15.4M
Q4 '212021-12-31-5.4M
Q3 '212021-09-3013.7M

Cost of Revenue Quarterly

PeriodEndingCost of Revenue
Q3 '192019-09-303.1M
Q2 '192019-06-302.4M
Q1 '192019-03-313.9M
Q4 '182018-12-313M
Q3 '182018-09-301.5M
Q2 '182018-06-301.1M
Q1 '182018-03-31788K
Q4 '172017-12-311.7M
Q3 '172017-09-302.4M
Q2 '172017-06-30903K
Q1 '172017-03-31340K

Operating Cash Flow Quarterly

PeriodEndingOperating Cash Flow
Q2 '262026-06-3024M
Q1 '262026-03-3148.7M
Q4 '252025-12-3145.9M
Q3 '252025-09-3013.1M
Q2 '252025-06-3015.8M
Q1 '252025-03-31-25.4M
Q4 '242024-12-3128.5M
Q3 '242024-09-3036.5M
Q2 '242024-06-3013.3M
Q1 '242024-03-3118.7M
Q4 '232023-12-318.1M
Q3 '232023-09-307.6M
Q2 '232023-06-30-82K
Q1 '232023-03-3133.9M
Q4 '222022-12-3153.5M
Q3 '222022-09-3020.5M
Q2 '222022-06-3011.9M
Q1 '222022-03-3152M
Q4 '212021-12-3127.6M
Q3 '212021-09-3020M

Free Cash Flow Quarterly

Operating cash flow minus capital expenditure.

PeriodEndingFree Cash Flow
Q2 '262026-06-3024M
Q1 '262026-03-3148.5M
Q4 '252025-12-3145.9M
Q3 '252025-09-3013.1M
Q2 '252025-06-3015.6M
Q1 '252025-03-31-25.7M
Q4 '242024-12-3127.8M
Q3 '242024-09-3035.9M
Q2 '242024-06-3012.9M
Q1 '242024-03-3118.6M
Q4 '232023-12-317.6M
Q3 '232023-09-307.2M
Q2 '232023-06-30-285K
Q1 '232023-03-3131.5M
Q4 '222022-12-3151.3M
Q3 '222022-09-3016.2M
Q2 '222022-06-305.3M
Q1 '222022-03-3147.1M
Q4 '212021-12-3125.4M
Q3 '212021-09-3018.3M

Shares Outstanding Quarterly

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

PeriodEndingShares Outstanding
Q2 '262026-06-3021.8M
Q1 '262026-03-3119.9M
Q3 '252025-09-3020.6M
Q2 '252025-06-3019.9M
Q1 '252025-03-3119.2M
Q3 '242024-09-3018.4M
Q2 '242024-06-3018M
Q1 '242024-03-3118.1M
Q3 '232023-09-3017.4M
Q2 '232023-06-3017.7M
Q1 '232023-03-3118M
Q4 '222022-12-3116.9M
Q3 '222022-09-3017.1M
Q2 '222022-06-3017.1M
Q1 '222022-03-3116.8M
Q4 '212021-12-3116.7M
Q3 '212021-09-3017.1M
Q2 '212021-06-3017.2M
Q1 '212021-03-3117.2M
Q4 '202020-12-3116.7M

EPS TTM

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.

PeriodEndingEPS
Q2 '262026-06-309.41
Q1 '262026-03-317.43
Q4 '252025-12-315.89
Q3 '252025-09-302.01
Q2 '252025-06-30-4.06
Q1 '252025-03-31-7.18
Q4 '242024-12-31-0.22
Q3 '242024-09-302.51
Q2 '242024-06-302.31
Q1 '242024-03-315.32
Q4 '232023-12-312.90
Q3 '232023-09-300.82
Q2 '232023-06-301.43
Q1 '232023-03-311.25
Q4 '222022-12-31-1.99
Q3 '212021-09-303.99
Q2 '212021-06-302.77
Q1 '212021-03-312.30
Q4 '202020-12-31-0.21
Q3 '202020-09-30-0.99